Showing 1731-1740 of 2105 results for "".
- Uplizna Safe and Effective for Adults Aged ≥50 Years with AQP4+ NMOSDhttps://practicalneurology.com/news/uplizna-safe-and-effective-for-adults-aged-50-years-with-aqp4-nmosd/2470418/People aged ≥50 years with aquaporin-4 antibody positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) who were treated with Uplizna (inebilizumab-cdon; Amgen, Dublin, Ireland) showed a reduced risk of attack compared with those receiving placebo, according to results of a post-hoc an
- MS Susceptibility Genes Introduced to Europe 5000 Years Ago According to Study Published in Naturehttps://practicalneurology.com/news/ms-susceptibility-genes-introduced-to-europe-5000-years-ago-according-to-study-published-in-nature/2470382/Genes associated with susceptibility for multiple sclerosis (MS) may have been introduced to Northern Europe 5000 years ago, according to new study results published in Nature. The study was conducted to investigate potential causes for the significantly greater prevalence of MS among Wh
- In Young Adults, Moderate-to-Heavy Drinking Linked to Higher Risk of Strokehttps://practicalneurology.com/news/in-young-adults-moderate-to-heavy-drinking-linked-to-higher-risk-of-stroke/2470059/According to a clinical study published in Neurology, people in their 20s and 30s who drink moderate to heavy amounts of alcohol may be more likely to have a stroke as young adults than people who drink low amounts or no alcohol. The more years that people drank moderately or heavily, the risk of
- Cognitive Decline Remains for Some 1 Year After Concussionhttps://practicalneurology.com/news/concussion-display-a-cognitive-decline-in-a-year-of-recovery/2469828/A new study published in Neurology, suggests individuals with mild traumatic brain injuries may be more likely to result in cognitive impairment, cognitive decline, or both 1 year later. O
- Yours, Truly--A Multicultural Storytelling Campaign--Launches to Bring Awareness to Nonmotor Symptoms of Parkinson Diseasehttps://practicalneurology.com/news/yours-truly-a-multicultural-storytelling-campaign-launches-to-bring-awareness-to-nonmotor-symptoms-of-parkinson-disease/2469763/A multicultural storytelling campaign, Yours, Truly , sharing the personal stories of people with Parkinson disease (PD), has launched. The aim of this campaign is to bring greater awareness and understanding of the nonmotor symptoms of PD
- Incidence of Concussion Rising in Young Womenhttps://practicalneurology.com/news/incidence-of-concussion-rising-in-young-women/2469680/A new study, presented at the 2021 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), shows that sports-related head injuries among young women (age 14 -18 years) has more than doubled. Young women athletes had concussion rates nearly twice as high as their men athletes when p
- Brivaracetam Now Approved for Focal Seizure Treatment in Children as Young as 1 Monthhttps://practicalneurology.com/news/brivaracetam-now-approved-for-focal-seizure-treatment-in-children-as-young-as-1-month/2469677/The Food and Drug Administration (FDA) has approved an expanded indication for brivaracetam (Briviact; Atlanta, GA) as monotherapy or adjunctive therapyto treat partial-onset seizures in individuals as young as 1 month of age. Brivaracetam is available as oral solution or tables or for intravenou
- Cenobamate Continuation for Over 6 Years Represents Long-Term Efficacy and Safetyhttps://practicalneurology.com/news/cenobamate-continuation-for-over-6-years-represents-long-term-efficacy-and-safety/2469643/In the long-term open-label extension of a randomized double-blind placebo-controlled study of adjunctive treatment for epilepsy with cenobamate (Xcopri; SK LIfe Science, Paramus, NJ)treatment duration averaged 6.25 years (200 mg median modal daily dose, range 50 to 400 mg). Initial enr
- Risdiplam Improvements in Motor Function Continue Over 1 Year of Treatment in Infancy to Adulthoodhttps://practicalneurology.com/news/risdiplam-improvements-in-motor-function-continue-over-1-year-of-treatment-in-infancy-to-adulthood/2469613/In the JEWELFISH study (NCT03032172), individuals age 1 to 60 years with spinal muscular atrophy (SMA) who were treated with risdiplam (Evrysdi; Genentech, South San Francisco, CA) had more than a twofold increase in SMN protein levels
- Deep Brain Stimulation Remains Effective for Parkinson Disease After 15 Yearshttps://practicalneurology.com/news/deep-brain-stimulation-remains-effective-for-parkinson-disease-after-15-years/2469605/According to a study published in Neurology, deep brain stimulation (DBS) continues to be effective for treating symptoms of Parkinson disease (PD) 15 years after implantation. Over a 15-year period, people with PD treated with DBS had a 75% reduction from baseline in dyskinesia, 59% less "O